Sanofi/Regeneron’s dupilumab hits targets in dermatitis trial
Sanofi and Regeneron’s experimental therapy dupilumab has hit primary and secondary targets in a late-stage trial assessing its effectiveness in patients with poorly controlled atopic dermatitis.
Read More
